First Manhattan’s Agios Pharmaceuticals AGIO Stock Holding History

First Manhattan’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-66,000	Closed	-$2.34M	–	1371
2020 Q1	$2.34M	Buy	+66,000	New	+$3.05M	0.02%	282

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

First Manhattan's AGIO Position: Q2 2020 in Review

First Manhattan sold out of Agios Pharmaceuticals (AGIO) in Q2 2020, closing a stake of 66,000 shares — an estimated $2.34M sold.

First Manhattan first reported a position in AGIO in Q1 2020 and held it in 1 quarter. The position peaked at $2.34M in Q1 2020. 216 funds tracked by Wall St. Rank hold AGIO as of Q2 2020.

First Manhattan reported no remaining Agios Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
First Manhattan sold 66,000 Agios Pharmaceuticals shares in Q2 2020, an estimated $2.34M.
First Manhattan first reported a position in Agios Pharmaceuticals in Q1 2020 and held it in 1 quarter.
First Manhattan's Agios Pharmaceuticals position peaked at $2.34M in Q1 2020.
216 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.